AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25344328
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) 0.5 g/kg plus standard treatment
Trial: 25344328
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo plus standard treatment
Trial: 16342925
Drug: Simulated imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated imatinib treatment (80% favorable survival times)
Trial: 16342925
Drug: Simulated imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated imatinib treatment (65% favorable survival times)
Trial: 16342925
Drug: Simulated imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated imatinib treatment (50% favorable survival times)
Trial: 9649993
Drug: Minimal-flow anaesthesia
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal-flow anaesthesia (0.5 L min-1 fresh gas inflow)
Trial: 9649993
Drug: Higher-flow anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-flow anaesthesia (3 L min-1 fresh gas flow)
Trial: 23123375
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg extended release oxybutynin daily
Trial: 31310186
Drug: Family phone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family phone calls and/or visits with patients, attendance at family therapy sessions, communication with inpatient staff about services available to families
Trial: 28337872
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ropivacaine (0.50%)
Trial: 28337872
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg ropivacaine (0.50%)
Trial: 28337872
Drug: 14 mg
RxNorm normalized name: iodine 0.14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg ropivacaine (0.50%)
Trial: 26159013
Drug: Peitu Shengjin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peitu Shengjin Recipe (PSR), one dose per day
Trial: 26159013
Drug: Seretide (50/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seretide (50/500 µg), twice per day
Trial: 10894991
Drug: L‐dopa +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐dopa + lisuride
Trial: 10894991
Drug: L‐dopa alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐dopa alone
Trial: 4059296
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g triletide
Trial: 4059296
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g triletide
Trial: 4059296
Drug: Dose correlation
RxNorm normalized name: diphenhydramine hydrochloride Oral Solution [Correct Dose Childrens Allergy Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose correlation
Trial: 29945918
Drug: Risankizumab 18
RxNorm normalized name: RISANKIZUMAB 180 mg in 1.2 mL SUBCUTANEOUS INJECTION, SOLUTION [Skyrizi]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 18 mg
Trial: 29945918
Drug: Risankizumab 90
RxNorm normalized name: Risankizumab 90.361 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 90 mg
Trial: 25006678
Drug: Ergocalciferol (50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergocalciferol (50,000 IU weekly for one month followed by 50,000 IU monthly)
Trial: 22643537
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (400 mg/day for 36 months)
Trial: 22643537
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (400 mg/day for 12 months)
Trial: 20391952
Drug: Octatropine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octatropine plus diazepam (Valpinax) 40 mg/2.5 mg twice daily for 6 weeks
Trial: 18272290
Drug: Nicotine (Nicorette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (Nicorette 2 mg gum)
Trial: 15721731
Drug: 500‐mg paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500‐mg paracetamol + 75‐mg caffeine
Trial: 15721731
Drug: 500‐mg paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500‐mg paracetamol + 125‐mg caffeine
Trial: 9861379
Drug: Chloroquine syrup
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine syrup (25 mg/kg)
Trial: 7898741
Drug: Conventional antiepileptic
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antiepileptic drugs (monotherapy)
Trial: 7898741
Drug: New antiepileptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antiepileptic agents
Trial: 2146130
Drug: Etodolac (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (200 to 300 mg b.i.d. or 200 mg t.i.d.)
Trial: 2146130
Drug: Etodolac (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (200 mg b.i.d.)
Trial: 2146130
Drug: Etodolac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (50 to 200 mg b.i.d.)
Trial: 2146130
Drug: Naproxen (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (250 to 375 mg b.i.d.)
Trial: 374176
Drug: Motilin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motilin infusion (0.34 pmol/kg/min for 60 min, followed by 0.68 pmol/kg/min for 60 min)
Trial: 374176
Drug: Motilin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motilin infusion (high dose)
Trial: 374176
Drug: Motilin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motilin infusion (low dose)
Trial: 26631103
Drug: 150-mg Artemisia
RxNorm normalized name: Artemisia vulgaris
DrugBank: Artemisia vulgaris root (DB14170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-mg Artemisia annua extract (ART) twice daily (BD)
Trial: 26631103
Drug: 300-mg Artemisia
RxNorm normalized name: Artemisia vulgaris
DrugBank: Artemisia vulgaris root (DB14170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg Artemisia annua extract (ART) twice daily (BD)
Trial: 23611363
Drug: Individual daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual daily pain treatment with acetaminophen, extended release morphine, buprenorphine transdermal patch, and/or pregabaline for 8 weeks
Trial: 23611363
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment and care
Trial: 19931345
Drug: Mandibular-implant overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular-implant overdentures
Trial: 12214785
Drug: Cognitive-behavioural programme
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural programme with 5-8 weekly home-visits
Trial: 7920454
Drug: Carbenoxolone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone (300 mg/day for 5 days) in normal subjects
Trial: 7920454
Drug: Carbenoxolone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone (300 mg/day for 5 days) in patients with renal disease
Trial: 2838979
Drug: Propranolol (75-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (75-100 mg/d)
Trial: 19502478
Drug: Parent Skills
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent Skills with Behavioral Couples Therapy (PSBCT)
Trial: 7518763
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 10 mg/kg twice daily for 10 days
Trial: 7518763
Drug: Cefaclor 10
RxNorm normalized name: cefaclor 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 10 mg/kg twice daily for 10 days
Trial: 28288601
Drug: Multimodal behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal behavioral intervention (MBI) treatment including telephone counseling, nicotine replacement therapy, mobile app support, multimedia text messages about TSE and smoking cessation.
Trial: 24837362
Drug: CE/BZA (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE/BZA (both doses)
Trial: 24837362
Drug: CE/BZA (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE/BZA (higher dose)
Trial: 2572181
Drug: Topical levocabastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical levocabastine applied twice daily
Trial: 1086728
Drug: Schwarz live,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz live, further attenuated measles virus vaccine at full dose (0.5 ml)
Trial: 1086728
Drug: Schwarz live,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz live, further attenuated measles virus vaccine at reduced doses (40%, 60%, or 80%)
Trial: 1086728
Drug: Schwarz live,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz live, further attenuated measles virus vaccine at reduced volume below 0.5 ml
Trial: 1086728
Drug: Schwarz live,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz live, further attenuated measles virus vaccine in children below 12 months of age
Trial: 21985174
Drug: Baseline imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline imaging after completion of 5-7 months of anticoagulant therapy
Trial: 21985174
Drug: No baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No baseline imaging after completion of 5-7 months of anticoagulant therapy
Trial: 27657899
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiation
Trial: 15630988
Drug: Combination treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatments with newer chemotherapy agents and optimal radiotherapy protocols
Trial: 15630988
Drug: Palliative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative treatment strategies
Trial: 9160851
Drug: Nicotine-containing cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine-containing cigarettes (0.1 mg per puff)
Trial: 9160851
Drug: Nicotine nasal
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine nasal spray (0.5 mg nicotine per spray)
Trial: 9160851
Drug: Vapor inhaler
RxNorm normalized name: Vapor Inhaler
DrugBank: Levmetamfetamine (DB09571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vapor inhaler (estimated 0.013 mg nicotine per inhalation)
Trial: 9160851
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 puffs, sprays, or inhalations)
Trial: 8226172
Drug: Radiation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation and simultaneous daily cisplatin
Trial: 8226172
Drug: Cisplatin containing
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin containing combination regimens with thoracic radiation
Trial: 8226172
Drug: Thoracic radiation
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic radiation therapy with or without single agent cisplatin
Trial: 8226172
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation and concurrent cisplatin containing combination therapies
Trial: 8226172
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation therapy and surgery
Trial: 3780826
Drug: SUR2647 combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUR2647 combination (2 g paracetamol X 2 on the day of operation, 1 g paracetamol X 2 on the following two days)
Trial: 3780826
Drug: SUR2647 combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUR2647 combination
Trial: 29383893
Drug: Tiaoshen Kaiyu
RxNorm normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiaoshen Kaiyu acupuncture plus standard treatment and psychological intervention
Trial: 29383893
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus psychological intervention (control group)
Trial: 8544547
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (up to 120 mg daily)
Trial: 8544547
Drug: Benztropine (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benztropine (active placebo, up to 1 mg twice daily)
Trial: 1860151
Drug: Rice-based oral
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice-based oral rehydration therapy (ORT)
Trial: 1860151
Drug: Sugar-based oral
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-based oral rehydration therapy (ORT)
Trial: 30576555
Drug: Methylprednisolone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (60 mg/d)
Trial: 30576555
Drug: Ketoprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (200 mg/d)
Trial: 25112302
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous saline solution)
Trial: 11285552
Drug: Immediate postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate postoperative radiation therapy (RT)
Trial: 11285552
Drug: Delayed radiation
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed radiation therapy (RT)
Trial: 11285552
Drug: Low-dose radiation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiation therapy (approximately 45-50 Gray (Gy))
Trial: 11285552
Drug: High-dose radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiation therapy (approximately 60-65 Gy)
Trial: 8179231
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of terfenadine twice daily for 1 week
Trial: 8179231
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 1 week
Trial: 2885946
Drug: Hemodilution (graded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodilution (graded venesection 250‐1000 ml during the first 2 days and dextran 40 infusions 500 ml daily for 5 days)
Trial: 30324496
Drug: Snapcare app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Snapcare app (App group) in addition to a written prescription
Trial: 30324496
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Conventional group) with a written prescription
Trial: 25437716
Drug: Transcervical intralesional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcervical intralesional vasopressin injection
Trial: 20334708
Drug: Pomegranate seed
RxNorm normalized name: pomegranate seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate seed oil (PSO) 400 mg twice daily
Trial: 18773990
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (E-Alone)
Trial: 18773990
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (E+P)
Trial: 15904514
Drug: Typhoid Vi
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhoid Vi polysaccharide vaccine
Trial: 7573074
Drug: Randomly assigned
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomly assigned intensity of exposure (0.1-40 fibers/ml)
Trial: 2099961
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous and oral Pentoxifylline
Trial: 7007058
Drug: Methenamine hippurate
RxNorm normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methenamine hippurate (MH), 1 g three times daily
Trial: 7007058
Drug: Placebo, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 g three times daily
Trial: 23190780
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hepatitis B vaccine)
Trial: 8950498
Drug: Inogatran (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inogatran (low molecular weight thrombin inhibitor)
Trial: 2031078
Drug: Recombinant alpha
RxNorm normalized name: Recombinant alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alpha 2b-interferon alone (6 weeks of placebo syrup followed by 16 weeks of recombinant alpha 2b-interferon, 5 x 10(6) u/m2 subcutaneously thrice weekly)
Trial: 2031078
Drug: Recombinant alpha
RxNorm normalized name: Recombinant alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alpha 2b-interferon with steroid priming (6 weeks of syrup prednisone followed by 16 weeks of recombinant alpha 2b-interferon)
Trial: 2031078
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (syrup vitamin B complex)
Trial: 31551223
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of Zushima tablet and western medicine
Trial: 18590256
Drug: Partial removal
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial removal with water spray cooled drills
Trial: 16091427
Drug: Non-study patients
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-study patients treated with chemotherapy
Trial: 11815986
Drug: Sandwich chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandwich chemotherapy (ifosfamide, etoposide, methotrexate, cisplatin, and cytosine arabinoside) followed by irradiation
Trial: 11815986
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (lomustine, vincristine, and cisplatin) followed by irradiation
Trial: 10881087
Drug: Mefloquine, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine, 250 mg per day in a single dose for six days, repeated three weeks later.
Trial: 10881087
Drug: Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimoniate (Glucantime), 20 mg/kg daily administered intravenously for 20 days.
Trial: 1799037
Drug: Triiodinated agents
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triiodinated agents
Trial: 29925490
Drug: Bictegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir alafenamide (25 mg)
Trial: 29925490
Drug: Boosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted protease inhibitor regimen
Trial: 29925490
Drug: Boosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted protease inhibitor group
Trial: 17149725
Drug: NS 2330
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NS 2330 (tesofensine) 0.25 mg
Trial: 17149725
Drug: NS 2330
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NS 2330 (tesofensine) 0.5 mg
Trial: 17149725
Drug: NS 2330
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NS 2330 (tesofensine) 1.0 mg
Trial: 24326799
Drug: Intravenous Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Oxytocin
Trial: 9803773
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of Ginkgo biloba extract (EGb)
Trial: 9803773
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of tacrine
Trial: 7652633
Drug: Meclofenamate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclofenamate (100 mg 3 times a day)
Trial: 7652633
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg 3 times a day)
Trial: 2523646
Drug: Isradipine (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5, 5, 7.5, or 10 mg twice daily)
Trial: 2523646
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of isradipine and atenolol